article thumbnail

How AI can help pharmacists

The Checkup by Singlecare

AI technology also supports clinical decision-making by analyzing patient data and checking for drug interactions, dosage errors, or allergies. However, it’s important to note that ChatGPT did not recommend specific dosages, and its success rate was not as high with complex patient cases.

article thumbnail

Health Data Management: Everything You Need to Know

Viseven

Typically, HCPs establish a most likely diagnosis and prescribe a medication, often a blockbuster drug, and choose dosage based on the patient’s body weight. If it does not help, they change the dosage or choose another drug if possible. Our solutions comply with GDPR, HIPAA, and numerous other industry standards.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Conversion Rate Optimization for Pharma: Boosting HCP & Patient Engagement

Pharma Marketing Network

Offer interactive tools like symptom checkers and dosage calculators. CRO best practices for patient engagement include: Clearly stating HIPAA compliance and data privacy policies. Use transparent data collection methods, privacy-centric CTAs, and ensure all content aligns with FDA and HIPAA guidelines.

HIPAA 52
article thumbnail

How to refuse to fill a prescription tactfully

SingleCare

That can help to make a conversation more open, and prevent embarrassment—and prevent HIPAA violations. If a pharmacist speaks to a patient about personal health information that can be easily overheard, the patient can file a HIPAA complaint. Show empathy No patient wants to hear that their prescription is being refused.

article thumbnail

The challenges of clinical data management: Can consent management software help?

Pharmaceutical Technology

Modern trial designs often require real-time data modelling and adaptive designs, which allow for changes in drug dosage, for example. As new approaches to trial design enter the scene, McInerney believes the complexity of CDM is increasing. This can empower patients and give them greater control over their clinical trial experience.”